We spoke to Professor Morie Getz at ASH 2018 about the current unmet needs in treatment of hereditary TTR amyloidosis, antisense technology, inotersen and the NEURO-TTR study.
1. What is hereditary TTR amyloidosis and what are the unmet needs in its treatment? (0:10)
2. Could you tell us a little about antisense technology and the mechanism of action of inotersen? (1:13)
3. What have been the major efficacy and safety findings of the NEURO-TTR study to date? (2:10)
4. What were the conclusions of the recent long-term update from the open-label extension of NEURO-TTR? (2:58)
5. What are the next steps in the clinical development of inotersen? (3:41)
Speaker’s disclosures: Morie A Gertz has received honoraria from Akcea and Ionis.
Filmed at the 60th American Society of Hematology (ASH) 2018 Annual Meeting, San Diego, CA, US, December 1–4, 2018.
Related Videos In Haematology
Efstathios Kastritis, EHA 2020: CYBORD in Amyloidosis and The ANDROMEDA Study
touchONCOLOGY joins Dr Efstathios Kastritis (Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece) at EHA25 Virtual to discuss the ANDROMEDA study (NCT03201965), and the efficacy and safety of daratumumab in combination with CYBORD for the treatment of newly-diagnosed light chain amyloidosis. Questions: What are the major therapeutic […]
George Goshua, EHA 2020: Endotheliopathy is Essential in COVID-19 Associated Coagulopathy
Dr George Goshua (Yale University School of Medicine, New Haven, CT, USA) shares with us his insights into the role of endotheliopathy in the development of coagulopathy in patients with COVID-19. Questions: 1. How common is coagulopathy in COVID-19 infection and who is at greatest risk? (0:03) 2. What is known about the role of […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!